“2025 saw important advances in both our MASH and acne programs,” said David Happel, Chief Executive Officer of Sagimet. “We completed our Phase 1 PK clinical trial of denifanstat and resmetirom combination and anticipate advancing the combination into a proof-of-concept Phase 2 clinical trial in F4 MASH, for which there are currently no approved treatments, in the second half of the year. In acne, positive 52-week data from our license partner Ascletis’ Phase 3 open-label acne trial with denifanstat will support Ascletis’ NDA that was accepted by the Chinese NMPA. We anticipate further exploring the potential role of FASN inhibition in acne in clinical development in 2026.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SGMT:
- Adobe downgraded, Palantir upgraded: Wall Street’s top analyst calls
- Sagimet Biosciences initiated with a Buy at Guggenheim
- Sagimet Biosciences price target raised to $37 from $29 at Clear Street
- Sagimet Therapeutics: Strengthened FASN-Inhibition Safety Profile and Advancing Phase 2 Programs Support Buy Rating
- Sagimet Biosciences Reports Positive Phase 3 Acne Data